SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

SCY-635 is a novel cyclophilin inhibitor and represents a new pharmacological class of inhibitors of HCV replication. SCY-635 has shown strong single-agent antiviral activity in a Phase 1b clinical study and has also demonstrated promising antiviral activity when combined with a wide range of mechanistically diverse anti-HCV agents. SCYNEXIS expects to initiate a Phase 2 study for SCY-635 in the second quarter of 2010.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Extended liver preservation technique shows promise for daytime transplants